Liang Ee Low

Dr. Liang Ee Low

Zhejiang University, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Advances in Colloid and Interface Science
Verified
Journal Article
Closed access
LLLiang Ee Low
Liang Ee Low
SSSangeetaprivya P. Siva
Sangeetaprivya P. Siva
YHYong Kuen Ho
Yong Kuen Ho
ECEng Seng Chan
Eng Seng Chan
BTBeng Ti Tey
Beng Ti Tey

1 June 2020 in Trends in Food Science & Technology
Verified
Journal Article
Closed access
WMWilliam Wachira Mwangi
William Wachira Mwangi
HLHui Peng Lim
Hui Peng Lim
LLLiang Ee Low
Liang Ee Low
BTBeng Ti Tey
Beng Ti Tey
ECEng Seng Chan
Eng Seng Chan

1 April 2019 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
LLLiang Ee Low
Liang Ee Low
LTLoh Teng-Hern Tan
Loh Teng-Hern Tan
Bey Hing GohBey Hing Goh
Bey Hing Goh
BTBeng Ti Tey
Beng Ti Tey
BOBoon Hoong Ong
Boon Hoong Ong
Patrick Tang Siah YingPatrick Tang Siah Ying
Patrick Tang Siah Ying

1 January 2017 in Carbohydrate Polymers
Verified
Journal Article
Closed access
LLLiang Ee Low
Liang Ee Low
BTBeng Ti Tey
Beng Ti Tey
Boon Hoong OngBoon Hoong Ong
Boon Hoong Ong
ECEng Seng Chan
Eng Seng Chan
Patrick Tang Siah YingPatrick Tang Siah Ying
Patrick Tang Siah Ying

1 August 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
LLLiang Ee Low
Liang Ee Low
JWJiahe Wu
Jiahe Wu
JLJiyoung Lee
Jiyoung Lee
BTBeng Ti Tey
Beng Ti Tey
Bey Hing GohBey Hing Goh
Bey Hing Goh
Daishun LingDaishun Ling
Daishun Ling

16 April 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Camille Keisha MahendraCamille Keisha Mahendra
Camille Keisha Mahendra
LTLoh Teng Hern Tan
Loh Teng Hern Tan
WLWai Leng Lee
Wai Leng Lee
WYWei Hsum Yap
Wei Hsum Yap
PPPriyia Pusparajah
Priyia Pusparajah
Bey Hing GohBey Hing Goh
Bey Hing Goh
Angelicin, a member of the furocoumarin group, is related to psoralen which is well known for its effectiveness in phototherapy. The furocoumarins as a group have been studied since the 1950s but only recently has angelicin begun to come into its own as the subject of several biological studies. Angelicin has demonstrated anti-cancer properties against multiple cell lines, exerting effects via both the intrinsic and extrinsic apoptotic pathways, and also demonstrated an ability to inhibit tubulin polymerization to a higher degree than psoralen. Besides that, angelicin too demonstrated anti-inflammatory activity in inflammatory-related respiratory and neurodegenerative ailments via the activation of NF-κB pathway. Angelicin also showed pro-osteogenesis and pro-chondrogenic effects on osteoblasts and pre-chondrocytes respectively. The elevated expression of pro-osteogenic and chondrogenic markers and activation of TGF-β/BMP, Wnt/β-catenin pathway confirms the positive effect of angelicin bone remodeling. Angelicin also increased the expression of estrogen receptor alpha (ERα) in osteogenesis. Other bioactivities, such as anti-viral and erythroid differentiating properties of angelicin, were also reported by several researchers with the latter even displaying an even greater aptitude as compared to the commonly prescribed drug, hydroxyurea, which is currently on the market. Apart from that, recently, a new application for angelicin against periodontitis had been studied, where reduction of bone loss was indirectly caused by its anti-microbial properties. All in all, angelicin appears to be a promising compound for further studies especially on its mechanism and application in therapies for a multitude of common and debilitating ailments such as sickle cell anaemia, osteoporosis, cancer, and neurodegeneration. Future research on the drug delivery of angelicin in cancer, inflammation and erythroid differentiation models would aid in improving the bioproperties of angelicin and efficacy of delivery to the targeted site. More in-depth studies of angelicin on bone remodeling, the pro-osteogenic effect of angelicin in various bone disease models and the anti-viral implications of angelicin in periodontitis should be researched. Finally, studies on the binding of angelicin toward regulatory genes, transcription factors, and receptors can be done through experimental research supplemented with molecular docking and molecular dynamics simulation.